Aktienanalyse zu QuidelOrtho Corp (QDEL)QDELQuidelOrtho Corp

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

QuidelOrtho Corp (QDEL) is currently trading at $14.74, which is below the average analyst price target of $18. However, the stock has a negative year-to-date change of -48.78% and a 20-day change of -12.10%, indicating significant downward pressure. The company's forward P/E ratio of 7.23 suggests it may be undervalued, but the recent negative earnings report and ongoing debt issues pose risks. Therefore, while there is potential for recovery, the current market sentiment and financial instability suggest holding rather than buying.

7 analysts cover QDEL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.